• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Aplastic Anemia - Pipeline Review, H1 2013 - Product Image

Aplastic Anemia - Pipeline Review, H1 2013

  • ID: 2596080
  • June 2013
  • 37 pages
  • Global Markets Direct

Aplastic Anemia - Pipeline Review, H1 2013

Summary

'Aplastic Anemia - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Aplastic Anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Aplastic Anemia. Aplastic Anemia - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Aplastic Anemia.
- A review of the Aplastic Anemia products under development by companies and universities/research institutes based on information derived from company READ MORE >

2
List of Tables 4
List of Figures 4
Introduction 5
REPORT COVERAGE 5
Aplastic Anemia Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Aplastic Anemia 7
Aplastic Anemia Therapeutics under Development by Companies 9
Mid Clinical Stage Products 10
Comparative Analysis 10
Early Clinical Stage Products 11
Comparative Analysis 11
Pre-Clinical Stage Products 12
Comparative Analysis 12
Aplastic Anemia Therapeutics – Products under Development by Companies 13
Companies Involved in Aplastic Anemia Therapeutics Development 14
GlaxoSmithKline plc 14
Pluristem Therapeutics Inc. 15
Aplastic Anemia – Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Drug Profiles 21
eltrombopag olamine - Drug Profile 21
Product Description 21
Mechanism of Action 21
R&D Progress 21
PLX Cells for Aplastic Bone Marrow - Drug Profile 24
Product Description 24
Mechanism of Action 24
R&D Progress 24
HemaXellerate - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
Aplastic Anemia Therapeutics – Drug Profile Updates 26
Aplastic Anemia Therapeutics - Dormant Products 30
Aplastic Anemia – Product Development Milestones 31
Featured News & Press Releases 31
Jun 20, 2013: Pluristem Therapeutics Announces Publication Of Preclinical Results Of PLX-RAD Cells In Journal PLOS ONE 31
Jun 07, 2013: Regen BioPharma Submits Responses To FDA Comments Regarding HemaXellerate Clinical Program 31
Apr 05, 2013: Regen BioPharma Files IND Application With FDA On HemaXellerate I Stem Cell Drug For Aplastic Anemia 32
Mar 18, 2013: Regen BioPharma Receives IND Number From FDA For HemaXellerate 32
Feb 21, 2013: Pluristem Receives FDA Orphan Drug Status Designation For Treatment Of Aplastic Anemia 33
Feb 05, 2013: Regen BioPharma Files Investigational New Drug Application With FDA On HemaXellerate I Stem Cell Drug For Aplastic Anemia 33
Aug 30, 2012: Pluristem Files For Orphan Drug Status With FDA For Use Of PLX Cells In Treatment Of Aplastic Anemia 34
Jul 23, 2012: Pluristem To Apply For Orphan Drug Status With FDA For Treatment Of Aplastic Bone Marrow 34
Jul 04, 2012: Platelet Drug Shows Clinical Benefits For Severe, Unresponsive Aplastic Anemia 35
Appendix 36
Methodology 36
Coverage 36
Secondary Research 36
Primary Research 36
Expert Panel Validation 36
Contact Us 37
Disclaimer 37

List of Tables
Number of Products Under Development for Aplastic Anemia, H1 2013 7
Products under Development for Aplastic Anemia – Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Comparative Analysis by Mid Clinical Stage Development, H1 2013 10
Comparative Analysis by Early Clinical Stage Development, H1 2013 11
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 12
Products under Development by Companies, H1 2013 13
GlaxoSmithKline plc, H1 2013 14
Pluristem Therapeutics Inc., H1 2013 15
Assessment by Monotherapy Products, H1 2013 16
Assessment by Stage and Route of Administration, H1 2013 18
Assessment by Stage and Molecule Type, H1 2013 20
Aplastic Anemia Therapeutics – Drug Profile Updates 26
Aplastic Anemia Therapeutics – Dormant Products 30

List of Figures
Number of Products under Development for Aplastic Anemia, H1 2013 7
Products under Development for Aplastic Anemia – Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Mid Clinical Stage Products, H1 2013 10
Early Clinical Stage Products, H1 2013 11
Pre-Clinical Stage Products, H1 2013 12
Assessment by Monotherapy Products, H1 2013 16
Assessment by Route of Administration, H1 2013 17
Assessment by Stage and Route of Administration, H1 2013 18
Assessment by Molecule Type, H1 2013 19
Assessment by Stage and Molecule Type, H1 2013 20

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos